Sumitomo Mitsui Trust Group, Inc. 13D and 13G filings for Takeda Pharmaceutical Company Limited:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-05 06:24 am Sale |
2023-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK |
Sumitomo Mitsui Trust Group, Inc. | 87,400,834 5.500% |
-6,198,700 (-6.62%) |
Filing |
| 2023-02-03 06:19 am Purchase |
2022-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK |
Sumitomo Mitsui Trust Group, Inc. | 93,599,534 5.900% |
2,685,800 (+2.95%) |
Filing |
| 2022-02-04 06:09 am Sale |
2021-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK |
Sumitomo Mitsui Trust Group, Inc. | 90,913,734 5.700% |
-3,120,300 (-3.32%) |
Filing |
| 2021-02-05 06:10 am Purchase |
2020-12-31 | 13G | Takeda Pharmaceutical Company Limited TAK |
Sumitomo Mitsui Trust Group, Inc. | 94,034,034 6.000% |
94,034,034 (New Position) |
Filing |